(Q35089127)

6 August 2017

1 reference

title

Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy (English)

1 reference

6 August 2017

1 reference

Tien Hoang

1

1 reference

6 August 2017

Joan H Schiller

series ordinal

2

1 reference

6 August 2017

publication date

1 August 2002

1 reference

Expert Review of Anticancer Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

393-401

1 reference

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.4.393

21 January 2018

Identifiers

DOI

10.1586/14737140.2.4.393

1 reference

6 August 2017

1 reference